NO20042124L - Thymosinforsterkning ved genetisk immunisering - Google Patents

Thymosinforsterkning ved genetisk immunisering

Info

Publication number: NO20042124L
Authority: NO; Norway
Prior art keywords: hepatitis; virus; thymosin; enhancement; genetic immunization
Prior art date: 2001-10-26

Application number

NO20042124A

Other languages

English (en)

Norwegian (no)

Inventor

Jack R Wands

Original Assignee

Rhode Island Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2004-05-24

Publication date

2004-05-24

2004-05-24 Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital

2004-05-24 Publication of NO20042124L publication Critical patent/NO20042124L/no

Links

102000007501 Thymosin Human genes 0.000 title abstract 4
108010046075 Thymosin Proteins 0.000 title abstract 4
230000003053 immunization Effects 0.000 title abstract 3
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 2
230000002068 genetic effect Effects 0.000 title 1
238000002649 immunization Methods 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 4
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
230000024932 T cell mediated immunity Effects 0.000 abstract 1
208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Zoology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

NO20042124A 2001-10-26 2004-05-24 Thymosinforsterkning ved genetisk immunisering NO20042124L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33063801P	2001-10-26	2001-10-26
PCT/US2002/034535 WO2003035010A2 (en)	2001-10-26	2002-10-28	Thymosin augmentation of genetic immunization

Publications (1)

Publication Number	Publication Date
NO20042124L true NO20042124L (no)	2004-05-24

Family

ID=23290629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042124A NO20042124L (no)	2001-10-26	2004-05-24	Thymosinforsterkning ved genetisk immunisering

Country Status (21)

Country	Link
US (1)	US20050054845A1 (pl)
EP (1)	EP1448223B1 (pl)
JP (1)	JP2005506997A (pl)
KR (1)	KR100902197B1 (pl)
CN (1)	CN1269524C (pl)
AT (1)	ATE382365T1 (pl)
BR (1)	BR0213554A (pl)
CA (1)	CA2464795A1 (pl)
CY (1)	CY1107371T1 (pl)
DE (1)	DE60224435T2 (pl)
DK (1)	DK1448223T3 (pl)
EA (1)	EA006743B1 (pl)
ES (1)	ES2299626T3 (pl)
IL (1)	IL161603A0 (pl)
MX (1)	MXPA04003867A (pl)
NO (1)	NO20042124L (pl)
NZ (1)	NZ532863A (pl)
PL (1)	PL370453A1 (pl)
PT (1)	PT1448223E (pl)
UA (1)	UA81613C2 (pl)
WO (1)	WO2003035010A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1835931A4 (en) *	2004-12-06	2008-12-17	Sciclone Pharmaceuticals Inc	ALPHA THYMOSINE PEPTIDES AS CANCER VACCINE ADJUVANTIES
EP2427213B1 (en)	2009-05-08	2015-04-01	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4079127A (en) *	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en) *	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) *	1978-01-23	1979-04-10	Hoffmann-La Roche Inc.	Synthesis of thymosin α1
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
TW224053B (pl)	1991-09-13	1994-05-21	Paul B Chretien
US5620896A (en) *	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US6288033B1 (en) *	1998-09-25	2001-09-11	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

2002
- 2002-10-28 ES ES02795564T patent/ES2299626T3/es not_active Expired - Lifetime
- 2002-10-28 PT PT02795564T patent/PT1448223E/pt unknown
- 2002-10-28 EP EP02795564A patent/EP1448223B1/en not_active Expired - Lifetime
- 2002-10-28 DE DE60224435T patent/DE60224435T2/de not_active Expired - Lifetime
- 2002-10-28 UA UA20040503963A patent/UA81613C2/ru unknown
- 2002-10-28 US US10/493,411 patent/US20050054845A1/en not_active Abandoned
- 2002-10-28 EA EA200400534A patent/EA006743B1/ru not_active IP Right Cessation
- 2002-10-28 MX MXPA04003867A patent/MXPA04003867A/es active IP Right Grant
- 2002-10-28 CA CA002464795A patent/CA2464795A1/en not_active Abandoned
- 2002-10-28 DK DK02795564T patent/DK1448223T3/da active
- 2002-10-28 JP JP2003537579A patent/JP2005506997A/ja active Pending
- 2002-10-28 PL PL02370453A patent/PL370453A1/pl unknown
- 2002-10-28 BR BR0213554-0A patent/BR0213554A/pt not_active IP Right Cessation
- 2002-10-28 IL IL16160302A patent/IL161603A0/xx unknown
- 2002-10-28 CN CNB028212770A patent/CN1269524C/zh not_active Expired - Fee Related
- 2002-10-28 NZ NZ532863A patent/NZ532863A/en unknown
- 2002-10-28 WO PCT/US2002/034535 patent/WO2003035010A2/en not_active Ceased
- 2002-10-28 AT AT02795564T patent/ATE382365T1/de not_active IP Right Cessation
- 2002-10-28 KR KR1020047006231A patent/KR100902197B1/ko not_active Expired - Fee Related
2004
- 2004-05-24 NO NO20042124A patent/NO20042124L/no not_active Application Discontinuation
2008
- 2008-03-28 CY CY20081100354T patent/CY1107371T1/el unknown

Also Published As

Publication number	Publication date
PL370453A1 (pl)	2005-05-30
WO2003035010A3 (en)	2003-12-04
KR20040089075A (ko)	2004-10-20
NZ532863A (en)	2006-07-28
DK1448223T3 (da)	2008-02-18
UA81613C2 (ru)	2008-01-25
EP1448223B1 (en)	2008-01-02
MXPA04003867A (es)	2005-06-17
DE60224435D1 (de)	2008-02-14
PT1448223E (pt)	2008-01-23
KR100902197B1 (ko)	2009-06-11
ATE382365T1 (de)	2008-01-15
CN1604789A (zh)	2005-04-06
EP1448223A4 (en)	2005-11-16
ES2299626T3 (es)	2008-06-01
EP1448223A2 (en)	2004-08-25
IL161603A0 (en)	2004-09-27
CN1269524C (zh)	2006-08-16
WO2003035010A2 (en)	2003-05-01
US20050054845A1 (en)	2005-03-10
BR0213554A (pt)	2004-10-26
EA006743B1 (ru)	2006-04-28
JP2005506997A (ja)	2005-03-10
CY1107371T1 (el)	2012-12-19
DE60224435T2 (de)	2009-01-02
EA200400534A1 (ru)	2004-12-30
CA2464795A1 (en)	2003-05-01

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
WO2006041866A3 (en)	2006-09-08	Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
EP1536009A4 (en)	2006-06-07	HLA-A24-RESTRICTED CANCERANTEPEPTIDE
AU2002360592A8 (en)	2003-07-09	Inhibitors of hepatitis c virus
WO2001058485A3 (en)	2002-01-10	Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2006086188A3 (en)	2006-11-23	Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
MXPA05005203A (es)	2006-01-27	Vacuna contra vhc.
WO2005007673A3 (en)	2007-11-22	Immunogenic peptides
DK1471936T3 (da)	2010-04-26	HIV-Vaccine og fremgangsmåde til anvendelse
WO2001096370A3 (en)	2003-01-03	Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
TW200641126A (en)	2006-12-01	N protein mutants of porcine reproductive and respiratory syndrome virus
MXPA06013388A (es)	2007-06-19	Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
WO2002057314A3 (en)	2003-05-30	Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
NO20042124L (no)	2004-05-24	Thymosinforsterkning ved genetisk immunisering
DK1949913T3 (da)	2010-10-04	Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
WO2004058807A3 (en)	2004-09-30	Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
PH12022550490A1 (en)	2023-02-06	Hepatitis b virus vaccines
WO2007121491A8 (en)	2008-01-10	Hcv vaccinations
WO2005056051A3 (en)	2005-09-29	Hepatitis b vaccines and compositions
ATE476197T1 (de)	2010-08-15	Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
MX2007002659A (es)	2007-05-16	Composicion vacunal contra el virus de la hepatitis c.
WO2001046696A3 (en)	2002-01-03	Methods and compositions for detecting hepatitis e virus
DE10393824D2 (de)	2005-08-11	Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze
RU2004104357A (ru)	2005-07-10	Вакцинный состав, потенцированный комбинацией днк и антигена
DE69433057D1 (de)	2003-09-25	Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
WO2005010035A3 (en)	2006-09-08	Alternate reading frame polypeptides derived from hepatitis c and methods of their use